Cardiol Therapeutics Inc.
Cardiol Therapeutics is a life sciences company developing therapies for heart disease that target fibrosis and inflammation. Its pipeline includes CardiolRx, a drug candidate for acute myocarditis and recurrent pericarditis, and CRD-38, a cannabidiol formulation administered under the skin for heart failure. The company is based in Oakville, Canada.
No SEC Form 4 filings for $CRDL in the last 30 days.
See all $CRDL insider activity →Cardiol Therapeutics (CRDL) has a $75M equity offering program with Jefferies LLC. Shares will be sold on Nasdaq at market prices. Proceeds will fund CardiolRx development, CRD-38 clinical trials, and general expenses. The program is optional and can be terminated by either party.
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) achieved its Phase III MAVERIC trial enrollment target of 110 patients ahead of schedule. The company plans to expand enrollment to up to 150 patients to strengthen the assessment of CardiolRx™'s efficacy in treating recurrent pericarditis. Topline results are now expected in mid-2027, with sufficient capital to fund the trial completion and a cash runway into Q1 2028.
Cardiol Therapeutics (CRDL) raised over $7M from warrant exercises, extending its cash runway to H1 2028. The funds will support its Phase III MAVERIC trial for recurrent pericarditis and regulatory preparations for CardiolRx™, its lead drug candidate.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning CRDL (Cardiol Therapeutics Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 5 bearish.
Recent CRDL coverage spans corporate actions, market movers and financial news.
The offering could dilute existing shareholders and put short‑term pressure on the stock, but proceeds may fund late‑stage drug development.
Earlier enrollment and trial expansion suggest stronger data potential, likely supporting the stock ahead of the mid‑2027 readout.
Modest capital infusion improves liquidity but is small relative to typical biotech financing.
The filing signals potential future capital raising but does not commit to an immediate issuance.
Positive trial advancement may boost near‑term price.
AlphAI scores every news story that mentions CRDL with an AI model for sentiment and relevance, and aggregates insider trades from Cardiol Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cardiol Therapeutics (CRDL) has a $75M equity offering program with Jefferies LLC. Shares will be sold on Nasdaq at market prices. Proceeds will fund CardiolRx development, CRD-38 clinical trials, and general expenses. The program is optional and can be terminated by either party.
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) achieved its Phase III MAVERIC trial enrollment target of 110 patients ahead of schedule. The company plans to expand enrollment to up to 150 patients to strengthen the assessment of CardiolRx™'s efficacy in treating recurrent pericarditis. Topline results are now expected in mid-2027, with sufficient capital to fund the trial completion and a cash runway into Q1 2028.
Cardiol Therapeutics (CRDL) raised over $7M from warrant exercises, extending its cash runway to H1 2028. The funds will support its Phase III MAVERIC trial for recurrent pericarditis and regulatory preparations for CardiolRx™, its lead drug candidate.
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) filed a US$150 million preliminary base shelf prospectus, allowing potential future offerings. The filing includes expanded program and expense disclosure following OSC staff review. The company is advancing CardiolRx™ for heart disease treatments and developing CRD-38 for inflammatory heart disease.
Five biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD
Summit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.
Several biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.
Andrew Peller (ADW.A) reached a 52-week high of $8.00 after completing a transaction with Fairfax. Algoma Central (ALC.TO) hit $25.25, reporting Q2 revenues of $258,273. Argo Graphene (C.ARGO) hit $1.15 after appointing a new CEO. Boralex (BLX) reached $37.24 following its acquisition by Brookfield. Bank of Montreal (BMO) hit $258.11 after selling Moneris. Other companies also hit 52-week highs with varying news.
The article compares small-cap medical stocks Aptorum Group (NASDAQ:APM) and Cardiol Therapeutics (NASDAQ:CRDL). It cites beta values of 0.3 for APM and 0.77 for CRDL, institutional ownership of 3.8% vs 12.5%, and insider ownership of 64.0% vs 5.3%. MarketBeat data shows CRDL consensus target price of $8.50 (upside 553.85%). It also states APM has higher revenue and earnings.
Cardiol Therapeutics Inc. announced the results of its 2025 Annual General Meeting of Shareholders, where all Management resolutions were approved. Dr. Timothy Garnett was elected to the Board of Directors, bringing extensive drug development and commercial expertise to the company. The company also provided updates on its clinical trials for CardiolRx™ in recurrent pericarditis and acute myocarditis, and the development of CRD-38 for heart failure.
